Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia

Andrès, Emmanuel; Mecili, Mustapha; Fothergill, Helen; Zimmer, Jacques; Vogel, Thomas; Maloisel, Frédéric

doi:10.1016/j.lpm.2012.02.010

Cited by 12 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 The analysis of the data revealed significant statistical differences between female and male for: 1) the bleeding score: 13±6.3 in females versus 8.4±4.1 in males (p=0.03); 2) the presence of a documented anemia: 7 % in females versus 4.3 % in males (p=0.04); and 3) the detection of antinuclear and/or antiphospholipid antibodies: 64.7 % versus 35.3 % (p<0.02) ( Table 1). For the first 2 parameters, the difference may be related to the presence of meno-and/or metrorrhagia and hematuria in female patients.…”

mentioning

confidence: 99%

What Impact for Sex Difference on Immune Thrombocytopenic Purpura?

Andrès¹

2016

Women Health Open J

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

What Impact for Sex Difference on Immune Thrombocytopenic Purpura?

Andrès¹

2016

Women Health Open J

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this study, the methyl-Pd treatment group had more female patients than those in the IVIg group. This limitation was due to the retrospective nature of this study, but no differences in clinical outcome or response to treatment were observed between genders in patients with ITP [15].…”

Section: Discussionmentioning

confidence: 99%

Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia

Kim

Choi

Moon

et al. 2019

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims Few studies have addressed whether there are differences in clinical efficacy between intravenous methylprednisolone (methyl-Pd) and intravenous immunoglobulin (IVIg) use. Methods We retrospectively compared platelet responses and toxicities associated with these two treatments in adult patients with immune thrombocytopenia. Patients received intravenous methyl-Pd therapy followed by oral prednisolone (Pd) from 1993 to 2002 and IVIg together with oral Pd from 2003 to 2008. Results Early response and maintenance of the response were assessed at 7 days and 6 months after treatment, respectively. Of the 87 patients enrolled, 77 (88.5%) were eligible for analysis. Early responses occurred in 30 of 39 patients (76.9%) receiving methyl-Pd versus 33 of 38 patients (86.6%) receiving IVIg ( p = 0.187). The response was maintained in 28 patients (71.8%) in the methyl-Pd arm and in 23 patients (60.5%) in the IVIg arm ( p = 0.187). The time to a complete response in the IVIg arm (6 days; range, 1 to 35) was shorter than that in the methyl-Pd arm (13.5 days; range, 2 to 29) ( p = 0.002). Side effects were mild and tolerable in both arms. Five years after initiating treatment, 7 of 18 patients (38.9%) and five of 14 patients (35.7%) were still maintaining a response in the methyl-Pd and IVIg arms, respectively. Conclusions These results indicate that neither the early response rate nor the long-term outcome differed between the methyl-Pd and IVIg treatments. However, IVIg induced a complete response more rapidly than did methyl-Pd.

show abstract

“…15,16 At diagnosis, a high prevalence of HMB has been previously reported. 4,[37][38][39][40][41] Our study suggests, however, that the proportion remains high despite management of ITP in a specialized centre. Of note, the prevalence of HMB throughout the course of disease was found to vary largely in different studies be much lower (17%-79%).…”

Section: Prevalence Of Hmbmentioning

confidence: 98%

“…At diagnosis, the reported prevalence ranged from 6% to 55%. 4,[37][38][39][40][41] None of these articles provided a clear definition of HMB. During the disease, the proportion of self-reported HMB ranged from −17% to 79%.…”

Section: Prevalence Of Hmbmentioning

confidence: 99%

Menstrual problems in chronic immune thrombocytopenia: A monthly challenge ‐ a cohort study and review

et al. 2022

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) is an autoimmune disease, in which autoantibodies attack the platelets and megakaryocytes. 1 This leads to thrombocytopenia and sometimes also platelet function defects. 2,3 The most common clinical features include petechiae, bruises, epistaxis, and gum bleeds. 4 A less frequently mentioned, but possibly very relevant symptom is heavy menstrual bleeding (HMB), as ITP often affects women of reproductive age. 1 HMB is defined as menstrual periods with abnormally heavy bleeding and/or prolonged bleeding (more than 7 days). 5,6 HMB poses a monthly challenge for women and often affects their quality of life. [7][8][9][10] The heavy blood flow leads to impairments in several domains, including physical, social, and emotional functioning, vitality and general

show abstract

Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia

Cited by 12 publications

References 21 publications

What Impact for Sex Difference on Immune Thrombocytopenic Purpura?

What Impact for Sex Difference on Immune Thrombocytopenic Purpura?

Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia

Menstrual problems in chronic immune thrombocytopenia: A monthly challenge ‐ a cohort study and review

Contact Info

Product

Resources

About